Colon Cancer Chemoprevention by Dietary Resveratrol
Colon Cancer Chemoprevention by Dietary Resveratrol
批准号:
7876998
负责人:
Lorne J Hofseth
金额:
$7.2万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2011-06-30
关键词:
AbateAddressAdverse effectsAffectAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsChemopreventionChemopreventive AgentChronicColitisColon CarcinomaCrohn&aposs diseaseDataDevelopmentDiseaseDisease remissionExhibitsFundingHealthInflammatoryInflammatory Bowel DiseasesMalignant NeoplasmsModelingOral AdministrationOrthomolecular TherapyPatientsPlayPreventionPreventiveRefractoryResveratrolRoleStilbenesSymptomsTestingTreatment outcomeUlcerative Colitisalternative treatmentcancer chemopreventioncancer riskcancer therapycolon carcinogenesisconventional therapydietary supplementsnovelpolyphenolprevent
中文摘要
描述(由申请人提供):
患有炎症性肠病[溃疡性结肠炎(UC)和克罗恩病(CD)]的人有很高的结肠癌风险。结肠炎的常规治疗可以减少疾病活动期并维持缓解,但治疗结果往往是边缘性的;患者变得难治;并且有危险的副作用。因此,补充和替代治疗仍然有希望减轻活动性疾病的症状。据估计,40%的炎症性肠病(IBD)患者使用某种形式的巨维生素治疗或草药/膳食补充剂。白藜芦醇(3,4 ',5-三羟基-反式-芪)是一种天然存在的多酚,其表现出多种有益健康的作用,包括抗氧化、抗炎、心脏保护和抗癌活性。它很快被认为是预防和治疗癌症的最有前途的天然分子之一。我们和另一个研究小组已经证明,口服白藜芦醇可加重动物结肠炎。这些研究提供了第一个原理证明,证明白藜芦醇可能有效治疗IBD,我们现在假设这将防止结肠癌的后续发展。这些研究应该提供重要的新数据,以确定这种天然化合物是否提供了一种新的安全方法,可用于预防结肠癌的发展。
英文摘要
DESCRIPTION (provided by applicant):
People with inflammatory bowel disease [ulcerative colitis (UC) and Crohn's disease (CD)] have a high colon cancer risk. Conventional treatment of colitis can reduce periods of active disease and maintain remission, but treatment outcomes are often marginal; patients become refractory; and there are dangerous side effects. Thus, complementary and alternative treatments remain promising for abating symptoms of active disease. An estimated 40% of inflammatory bowel disease (IBD) patients use some form of megavitamin therapy or herbal/dietary supplement. Resveratrol (3,4',5-Trihydroxy-trans-stilbene) is a naturally occurring polyphenol that exhibits pleiotropic health beneficial effects including anti-oxidant, anti-inflammatory, cardioprotective and anti-cancer activities. It is quickly being recognized as one of the more promising natural molecules in the prevention and treatment of cancer. We and one other group have demonstrated that oral administration of resveratrol alleviates colitis in animals. These studies have provided the first proof-of-principle demonstration that resveratrol may be effective in the treatment of IBD, and we now hypothesize that this will prevent the subsequent development of colon cancer. These studies should provide important new data that will determine if this natural compound provides a new and safe approach that will be useful in preventing the development of colon cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer
-
批准号:10524156
-
项目类别:
-
资助金额:$5.2万
-
财政年份:2020
-
负责人:Lorne J Hofseth
-
依托单位:
Administrative Supplement to Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent color cancer
-
批准号:10596870
-
项目类别:
-
资助金额:$9.12万
-
财政年份:2020
-
负责人:Lorne J Hofseth
-
依托单位:
Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer
-
批准号:10737737
-
项目类别:
-
资助金额:$15.79万
-
财政年份:2020
-
负责人:Lorne J Hofseth
-
依托单位:
Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer
-
批准号:10543988
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2020
-
负责人:Lorne J Hofseth
-
依托单位:
Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer
-
批准号:10319568
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2020
-
负责人:Lorne J Hofseth
-
依托单位:
Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer
-
批准号:9906384
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2020
-
负责人:Lorne J Hofseth
-
依托单位:
Colon cancer chemoprevention by the anti-inflammatory drug, Quinacrine
-
批准号:8511242
-
项目类别:
-
资助金额:$7.25万
-
财政年份:2013
-
负责人:Lorne J Hofseth
-
依托单位:
Colon cancer chemoprevention by the anti-inflammatory drug, Quinacrine
-
批准号:8624672
-
项目类别:
-
资助金额:$7.03万
-
财政年份:2013
-
负责人:Lorne J Hofseth
-
依托单位:
Targeting Protein Arginine Deiminases to Prevent Colitis and Colon Cancer
-
批准号:8279224
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2011
-
负责人:Lorne J Hofseth
-
依托单位:
Targeting Protein Arginine Deiminases to Prevent Colitis and Colon Cancer
-
批准号:8505408
-
项目类别:
-
资助金额:$30.76万
-
财政年份:2011
-
负责人:Lorne J Hofseth
-
依托单位:
Targeting Protein Arginine Deiminases to Prevent Colitis and Colon Cancer
-
批准号:8688165
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2011
-
负责人:Lorne J Hofseth
-
依托单位:
Targeting Protein Arginine Deiminases to Prevent Colitis and Colon Cancer
-
批准号:8874142
-
项目类别:
-
资助金额:$32.73万
-
财政年份:2011
-
负责人:Lorne J Hofseth
-
依托单位:
Targeting Protein Arginine Deiminases to Prevent Colitis and Colon Cancer
-
批准号:8089907
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2011
-
负责人:Lorne J Hofseth
-
依托单位:
Colon Cancer Chemoprevention by Dietary Resveratrol
-
批准号:7747257
-
项目类别:
-
资助金额:$7.2万
-
财政年份:2009
-
负责人:Lorne J Hofseth
-
依托单位:
INTERVENTION OF AUTOIMMUNE DISEASES BY A NOVEL ANTI-INFLAMMATORY MOLECULE
-
批准号:7959765
-
项目类别:
-
资助金额:$3.7万
-
财政年份:2009
-
负责人:Lorne J Hofseth
-
依托单位:
NITRIC OXIDE DRIVES RETINOBLASTOMA PATHWAY CHANGES IN INFLAMMATION AND CANCER
-
批准号:7720812
-
项目类别:
-
资助金额:$17.72万
-
财政年份:2008
-
负责人:Lorne J Hofseth
-
依托单位:
Sphingosine Kinase as a Target for Cancer Chemoprevention
-
批准号:7587654
-
项目类别:
-
资助金额:$8.06万
-
财政年份:2008
-
负责人:Lorne J Hofseth
-
依托单位:
Sphingosine Kinase as a Target for Cancer Chemoprevention
-
批准号:7686710
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2008
-
负责人:Lorne J Hofseth
-
依托单位:
RETINOBLASTOMA GENE IN INFLAMMATION AND CANCER
-
批准号:7610471
-
项目类别:
-
资助金额:$12.09万
-
财政年份:2007
-
负责人:Lorne J Hofseth
-
依托单位:
COBRE: USC: RETINOBLASTOMA GENE IN INFLAMMATION AND CANCER
-
批准号:7381897
-
项目类别:
-
资助金额:$9.79万
-
财政年份:2006
-
负责人:Lorne J Hofseth
-
依托单位:
海外基金